About US
Contact us
-
GE to divest its Biopharma business to Danaher for $21.4bnUS-based conglomerate General Electric (GE) has entered into a definitive agreement to divest its Biopharma business to science and technology innovator Danaher for approximately $21.4bn. As per the2019/2/27
-
Roche to acquire gene therapy specialist Spark Therapeutics for $4.8bnRoche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy companySpark Therapeuticsfor $114.50 per share, corresponding to a total of around $4.8bn on2019/2/26
-
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patientsGlobal pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse2019/2/26
-
Congressman aims to break pharma’s insulin ‘pricing monopoly’ by legalizing Canadian importsU.S. legislators have been introducing bills left and right proposing a variety of methods for bringing down drug prices. Now,Vermont's congressman is zeroing in on a specific class of diabetes medic2019/2/25
-
GSK-Bharat vaccine deal; Dr. Reddy’s roller coaster; Sandoz sells U.S. genericsBy scooping up GlaxoSmithKline's Chiron Behring Vaccines subsidiary, Bharat Biotech hastaken another step toward its goal ofbecomingthe world's largest vaccine maker in terms of product numbers. Dr.2019/2/25
-
Pipeline-hungry Bayer antes up on Vitrakvi, just as Roche’s would-be rival gets faster FDA reviewEager to pump up its pipeline—and hungry for present-day sales—Bayer has taken its chance to carve a piece out of Eli Lilly's $8 billion Loxo Oncology buyout. German drugmaker decided totakefull cont2019/2/20
-
Egalet's 70% price increase shows the buy-and-hike strategy is alive and wellThink the entire pharma industry has moved past the old strategy of buying drug rights, jacking up prices and reaping the rewards? Think again. Big Pharma may be limiting hikes to the single dig2019/2/20
-
NICE recommends Roche’s breast cancer drug pertuzumabThe UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Roche’s Perjeta (pertuzumab) by the National Health Service (NHS) to treat early HER2-positive breast canc2019/2/19
-
Merck Group and Pfizer announce positive results for combo therapy for RCCPfizer and German-based Merck Group have published promising interim results from their Phase III JAVELIN Renal 101 trial evaluating the efficacy and safety of Bavencio (avelumab) and Inlyta (axitini2019/2/19
-
Swayed by discounts, NICE finally backs Roche's Perjeta for postsurgery breast cancerLooks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer in England. After two previous rejections, the cost watchdogs at the Na2019/2/18